Antiviral agent 83

Antiviral agent 83 (Compound 13B) (10 μM; 48 h) inhibits HPV-16 PsVs infection in HeLa cells with high efficacy and low cytotoxicity, the virus inhibition rate is 83.33%, and the cytotoxicity is 5.71%^[1].
Antiviral agent 83 (48 h) inhibits HPV-16 PsVs with an IC₅₀ of 8.84 μM and exhibits low cytotoxicity in HeLa and VK2/E6E7 cells, with CC₅₀ values of 62.14 μM and 89.08 μM, respectively, resulting in high selectivity indices of 7.03 and 10.08^[1].
Antiviral agent 83 (0.625-10 μM; 48 h) potently inhibits infection by high-risk HPV-16, -18, -31, and -45 PsVs in HeLa cells with IC₅₀ values ranging from 7.80 to 12.45 μM^[1].
Antiviral agent 83 (5-20 μM; 1 h or 4 h preincubation; 48 h total incubation) directly inactivates HPV-45 PsVs in a dose- and time-dependent manner, with increased inhibition observed with longer pre-treatment durations^[1].
Antiviral agent 83 (10 μM; 4 h) disrupts the morphological integrity of HPV-45 PsVs when incubated at 10 μM for 4 h^[1].
Antiviral agent 83 binds specifically and with high affinity to HPV-16 L1 protein, with a K_d of 93.6 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.